1Kearney D, Byrne A, Crean P, et al. Optimal suppression of thromboxane A2 for formation by aspirin during pereutaneous transluminal coronary angioplasty:no additional effect of a selec tire cyclooxygenase-2 inhibitor. J Am Coll Cardiol, 2004, 43: 526.
2Herlitz J, Holm J, Peterson, M, et al, Effect of fixed how-dose warfarin added to aspirin in the long term after acute myocardial in farction: the Lo WASA Study. Eur Heart J, 2004,25: 232.
3Zibaeenezhad MJ, Mowla A, Sorbi MH. Warfarin and aspirin versus aspirin alone in patients with acute myocardial infarction: a pilot study Angiology, 2004,55 : 17.
4Peerlinck K,De Lepeleive I,Goldberg M, et al. MK-383 (L-700, 462), a selective nonpeptide platelet glycoprotein Ⅱb/Ⅲa antag onist,is active in man. Circulation, 1993,88:1512.
6Ferguson JJ. Meeting highlights. XIX congress of the European society of cardiology. Circulation, 1997,96:3818.
7Karvouni E, Katritsis DG, Loannidis JP. Intravenous glycoprorein, Ⅱb/Ⅲa receptor antagonists reduce mortality after pereu taneous coronary interventions. J Am Coll Cardiol, 2003,41:26.
8Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. 2002, Available at :http://www.ace. org/clinical/guidelines/unstable/unstable/pdf.
9The RESTORE Investigators. Effects of platelet glycoprotein Ⅱb/Ⅲa blockade with tirofiban on adverse cardiac events in pa tients with unstable angina of acute myocardial infarction undergoing coronary angioplasty. Circulation, 1997, 96:1445.
10Boersma E, Harrington RA, Moliterno DJ, et al. Platelet gty coprotein Ⅱb/Ⅲa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials, Lancet, 2002, 359 : 189.
